Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 27, 2005. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares and American Depositary Receipts (ADRs).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting specific share transactions and does not contain financial statements or performance metrics.
Material Changes
The filing details the following material changes in director and trust interests:
- GSK Trust Transfer: On January 26, 2005, Abacus (GSK) Trustees Limited transferred 8,698 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. Directors Dr. J-P Garnier, Dr. T Yamada, and Mr. J D Coombe hold interests in the GSK Trust as potential beneficiaries.
- Dr. J-P Garnier ADR Increase (Mid-Term Plan): On January 27, 2005, Dr. Garnier increased his interest by 1,282.316 Ordinary Share ADRs at $46.460 per ADR following dividend reinvestment.
- Dr. J-P Garnier ADR Increase (Performance Plan): On January 27, 2005, Dr. Garnier increased his interest by 279.161 Ordinary Share ADRs at $46.460 per ADR following dividend reinvestment.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is strictly a regulatory disclosure of share ownership changes.
Investor Verification Checklist
- Verify the total number of shares held by Dr. J-P Garnier post-transaction to assess insider ownership concentration.
- Confirm the impact of the 8,698 share transfer from the GSK Trust on the company's treasury stock or outstanding share count.
- Review the dividend reinvestment price of $46.460 per ADR against the market price on January 6, 2005, to ensure transaction accuracy.
- Check subsequent filings for any further changes in the interests of Dr. T Yamada and Mr. J D Coombe regarding the GSK Trust.